Rank |
Status |
Study |
1 |
Recruiting
|
Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Conditions: |
Dyspepsia; Compliance; Depression |
Interventions: |
Drug: Omeprazole; Drug: Flupentixol and Melitracen Tablets(for Dyspepsia symptoms) + Omeprazole; Drug: Flupentixol and Melitracen Tablets(for depression symptoms) + Omeprazole; Drug: Flupentixol and Melitracen Tablets(without explanation) + Omeprazole |
Outcome Measures: |
compliance of antidepressant medication; Dyspepsia symptom questionnaire; psychiatric symptom on Hospital Anxiety and Depression Scale; quality of life rating; adverse reaction |
|
2 |
Unknown †
|
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
Conditions: |
Aspirin; Dyspepsia |
Interventions: |
Drug: esomeprazole; Drug: Famotidine |
Outcome Measures: |
Treatment success : The HKDI is less than 16. Treatment was considered to have failed if a patient had taken medication for Dyspepsia (other than antacids) during the study period; Treatment success: no significant Dyspepsia defined by the Global Dyspepsia Score |
|
3 |
Unknown †
|
Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia
Conditions: |
Functional Dyspepsia; Gastric Emptying; Gastric Accommodation |
Interventions: |
Drug: Itopride,; Drug: Placebo |
Outcome Measures: |
To assess the effect of Itopride on Gastric Emptying,accommodation and capacity of tolerating a nutrient drink in patients with Functional Dyspepsia; To assess the effect of Itopride on symptom improvement in patient with Functional Dyspepsia |
|
4 |
Recruiting
|
Acupuncture for Patients With Function Dyspepsia
Conditions: |
Functional Dyspepsia; Postprandial Distress Syndrome |
Interventions: |
Other: acupuncture; Other: sham acupuncture |
Outcome Measures: |
The proportion of participants reporting complete absence of dyspeptic symptoms; validated Leeds Dyspepsia Questionnaire; Nepean Dyspepsia index; adverse events in each group |
|
5 |
Unknown †
|
Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia
Condition: |
Functional Dyspepsia |
Intervention: |
Drug: Acthrel |
Outcome Measures: |
Heart rate variability; Stress profile; plasma protein levels; BASC 2 profile; STICSA-C; GI symptom severity scale |
|
6 |
Recruiting
|
Ghrelin and Gastric Emptying in Children With Functional Dyspepsia
Condition: |
Functional Dyspepsia |
Intervention: |
|
Outcome Measures: |
Children with FD: exploration of relationships between ghrelin concentration, liquid gastric emptying, and Dyspepsia subtype; Children with FD: SUBJECTIVE SYMPTOM SEVERITY and correlations between plasma ghrelin concentrations (acyl and desacyl) and gastric emptying. |
|
7 |
Unknown †
|
Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition
Condition: |
Functional Dyspepsia |
Interventions: |
Drug: Gabapentin; Drug: Placebo |
Outcome Measures: |
The primary outcome will be the adequacy of symptom control during the last week of the study.; Secondary outcomes equate Dyspepsia symptoms with quality of life. The Nepean Dyspepsia Index scores patients on five categories while the Global Overall Symptom Scale measures the severity of Dyspepsia on a 1-7 scale. |
|
8 |
Unknown †
|
Mirtazapine Versus Placebo in Functional Dyspepsia
Condition: |
Functional Dyspepsia |
Intervention: |
Drug: Mirtazapine |
Outcome Measures: |
Difference in Dyspepsia symptom scores week 8 versus week 0; Individual symptom severities; Nepean Dyspepsia index for quality of life in functional Dyspepsia |
|
9 |
Not yet recruiting
|
Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia
Condition: |
Dyspepsia |
Interventions: |
Drug: Rebamipide; Drug: Placebo (for Esomeprazole); Drug: Esomeprazole |
Outcome Measures: |
Dyspepsia symptoms; quality of life |
|
10 |
Recruiting
|
Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial
Condition: |
Functional Dyspepsia |
Intervention: |
Device: Acupuncture |
Outcome Measures: |
Proportion of responders; Nepean Dyspepsia Index - Korean version (NDI-K); EuroQol-5 Dimension (EQ-5D); Functional Dyspepsia-Related Quality of Life (FD-QoL) Questionnaire; Beck's Depression Inventory (BDI); The State-Trait Anxiety Inventory (STAI); Ghrelin hormone measurement (1. Total ghrelin, 2. Deacylated ghrelin); Genotype analysis by Axiom® exome genotyping arrays |
|
11 |
Unknown †
|
Functional Dyspepsia - Effect of Acid-Reducing Treatment and Information on Various Types of Dysmotility
Condition: |
Dyspepsia |
Interventions: |
Procedure: Individualized and comprehensive information; Drug: Lanzo Melt |
Outcome Measure: |
Improvement of symptom score |
|
12 |
Recruiting
|
BRAVO Study for Functional Dyspepsia
Conditions: |
Dyspepsia; Gastroesophageal Reflux |
Interventions: |
Drug: Esomeprazole 20mg; Other: Placebo |
Outcome Measures: |
The primary outcome measure is the proportion of patients who report positive response to adequate relief of dyspeptic symptoms at week 8.; The secondary outcome measures include dyspeptic symptom scores, symptom association probability of dyspeptic symptoms in relation to esophageal pH of less than 4 as measured at 1 cm above SCJ. |
|
13 |
Recruiting
|
SSRI Study for Functional Dyspepsia (SS)
Conditions: |
Dyspepsia; Anxiety; Depression |
Interventions: |
Drug: Escitalopram; Other: Placebo |
Outcome Measures: |
To evaluate the change of serotonin and ghrelin level in blood plasma before and after treatment; To measure expression of serotonin and ghrelin blood plasma, the rate of adequate relief using global symptom assessment, symptom scores and the fullness rating of the Fullness Rating Scale (FRS) during satiety test |
|
14 |
Unknown †
|
Mucosal Barrier Defects in Functional Dyspepsia by Confocal Laser Endomicroscopy
Condition: |
Functional Dyspepsia |
Intervention: |
|
Outcome Measures: |
Specific microscopic changes in the gastric mucosa as seen under the confocal endomicroscope; the relationship among minimal changes, FD symptoms , neuropeptides and immune responses. |
|
15 |
Recruiting
|
Comparison of Pantoprazole and Ranitidine in Dyspepsia
Condition: |
Dyspepsia |
Interventions: |
Drug: Pantoprazole; Drug: Ranitidine |
Outcome Measures: |
Visual analogue scale score; Need for additional drug |
|
16 |
Unknown †
|
Safety Study of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia
Conditions: |
Functional Dyspepsia(FD) Was Studied; Effect of Simotang on FD Was Studied |
Intervention: |
|
Outcome Measures: |
Improvement of gastrointestinal Symptom as efficacy and the Number of Participants with Adverse Events as a Measure of Safety; Chinese version of the Nepean Dyspepsia Index as a Measure of efficacy |
|
17 |
Unknown †
|
The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia
Condition: |
Nonulcer Dyspepsia |
Interventions: |
Drug: Pantoprazol; Drug: Folic Acid |
Outcome Measure: |
Effectiveness of pantoprazole treatment in patients with functional Dyspepsia measured by symptoms scale. |
|
18 |
Not yet recruiting
|
The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia
Condition: |
Functional Dyspepsia |
Interventions: |
Drug: Rikkunshito; Drug: Rikkunshito placebo |
Outcome Measures: |
Global assessment of overall treatment efficacy (OTE); Global overall symptom (GOS) |
|
19 |
Unknown †
|
Does Visceral Manipulation Works in Treating Functional Dyspepsia?
Condition: |
Functional Dyspepsia |
Interventions: |
Procedure: Visceral Manipulation; Drug: PPIs and/or Domperidone |
Outcome Measure: |
FD symptoms: Bothersome postprandial fullness
/ Early satiation / Epigastric pain / Epigastric burning |
|
20 |
Recruiting
|
Rifaximin for Functional Dyspepsia
Condition: |
Functional Dyspepsia |
Interventions: |
Drug: Rifaximin; Drug: Placebo |
Outcome Measures: |
Adequate relief of dyspeptic symptoms at end of treatment; Individual dyspeptic symptom scores |
|